0GP7 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Medivir AB engages in the development of pharmaceuticals products. The firm focuses on the discovery and development of transformative active cancer drugs. Its portfolio includes proprietary pipelines such as remetinostat, birinapant, MV-818, MV-828, and MIV-711 projects, and partnership pipeline which covers xerclear and MIV-802 project. The company was founded in 1988 and is headquartered in Huddinge, Sweden.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
0GP7 has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company